Regulation of NADPH Oxidase by Angiotensin II-Role in Myometrial Hypertrophy
血管紧张素 II 调节 NADPH 氧化酶在子宫肌肥大中的作用
基本信息
- 批准号:7208975
- 负责人:
- 金额:$ 7.45万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2006
- 资助国家:美国
- 起止时间:2006-03-20 至 2010-02-28
- 项目状态:已结题
- 来源:
- 关键词:Angiotensin IIAngiotensin II ReceptorAngiotensinsApoptosisBiochemicalBlood VesselsCalciumCardiac MyocytesCatalytic DomainCaveolaeCaveolinsCell LineCell membraneCellsCellular biologyDataDiscipline of obstetricsElementsEpidermal Growth Factor ReceptorFailureFetal GrowthFibrosisGTP-Binding ProteinsGene FamilyGenerationsGonadal Steroid HormonesGrowthGrowth FactorHandHumanHyperplasiaHypertrophyImmunohistochemistryInfectionIschemiaLeiomyomaLinkLocalizedMechanicsMediatingMembraneMetabolismMethodsMinorMolecular BiologyMolecular ChaperonesMuscle ContractionMuscle ProteinsMyocardiumMyometrialNADPH OxidasePathologyPathway interactionsPhysiologicalPhysiological ProcessesPhysiological reperfusionPlasmaPlayPregnancyPregnant WomenPremature BirthProcessProductionProtein BiosynthesisProtein IsoformsProteinsReactive Oxygen SpeciesReceptor, Angiotensin, Type 1RegulationRenin-Angiotensin SystemReperfusion TherapyResearchReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSignal Transduction PathwaySiteSmooth MuscleSmooth Muscle MyocytesSomatotropinSpecificityStressStretchingTissuesTranscriptional ActivationUncertaintyUp-RegulationUterusVascular Smooth MuscleVascular remodelingVasopressinsangiogenesiscarcinogenesiscaveolin 1cell typecytokineinhibitor/antagonistinterestmyometriumprotein expressionreceptorrelease of sequestered calcium ion into cytoplasmuterine smooth muscle cell
项目摘要
DESCRIPTION (provided by applicant): Uterine hypertrophy is a physiological process occurring in pregnancy to accommodate fetal growth and the need for contraction at delivery. Growth factors, sex hormones and cytokines are known to stimulate uterine smooth muscle growth during normal pregnancy or fibrosis. Angiotensin II is a well documented vascular smooth muscle growth factor. However, the role of angiotensin II in uterine growth is not well defined, despite the fact that its concentration is increased and there is a significant switch in myometrial receptor subtype towards the type 1 angiotensin II receptor in pregnant women. NADPH oxidase isoforms, via generation of reactive oxygen species, have been shown to be responsible for the growth promoting effect of angiotensin II which is mediated by type 1 receptor in vascular smooth muscle and cardiac myocytes. We have identified several NADPH oxidase isoforms in human myometrium and in a human uterine smooth muscle cell line. We also found that a NADPH oxidase inhibitor blocked angiotensin ll-induced production of reactive oxygen species as well as uterine smooth muscle protein synthesis. Therefore, we hypothesize that angiotensin II plays an important role in myometrial growth during pregnancy via activation of NADPH oxidase, which is dependent on the type 1 angiotensin II receptor and downstream signaling pathways. We further hypothesize that NADPH oxidase is localized and activated in caveolae, the plasma membrane structures where several elements of a proposed signal transduction pathway were found. These include angiotensin II type 1 receptor, the catalytic unit of NADPH oxidase isoform 1 (Nox1), G proteins, and epidermal growth factor receptor. We will employ a combination of molecular biology, cell biology, and biochemical methods to study, in the uterine smooth muscle cell line, the following specific aims: 1) The role of angiotensin II in regulation of NADPH oxidase expression and activation in myometrial smooth muscle cells; and 2) The role of NADPH oxidase in angiotensin II receptor-mediated myometrial growth (hypertrophy) and signaling. Currently there is a great deal of interest in the role of reactive oxygen species in obstetric pathologies. It is known that many cases of preterm delivery are associated with infection where cytokines induce reactive oxygen species production. Excessive generation of reactive oxygen species contributes to contractile failure, rigor and calcium overload. Thus we predict that the angiotensin II-NADPH oxidase-reactive oxygen species pathway plays a role in labor process as well.
描述(由申请人提供):子宫肥大是怀孕期间发生的一种生理过程,以适应胎儿生长和分娩时收缩的需要。已知生长因子、性激素和细胞因子在正常妊娠或纤维化期间刺激子宫平滑肌生长。血管紧张素II是一种血管平滑肌生长因子。然而,血管紧张素II在子宫生长中的作用尚未明确,尽管事实上其浓度增加,并且在妊娠妇女中子宫肌层受体亚型向1型血管紧张素II受体有显著转变。NADPH氧化酶亚型通过产生活性氧,已被证明负责血管紧张素II的生长促进作用,其由血管平滑肌和心肌细胞中的1型受体介导。我们在人子宫肌层和人子宫平滑肌细胞系中鉴定了几种NADPH氧化酶亚型。我们还发现,NADPH氧化酶抑制剂阻断血管紧张素II诱导的活性氧的产生以及子宫平滑肌蛋白质的合成。因此,我们假设血管紧张素II通过激活NADPH氧化酶在妊娠期间子宫肌层生长中起重要作用,NADPH氧化酶依赖于1型血管紧张素II受体和下游信号通路。我们进一步假设NADPH氧化酶定位于细胞膜小窝并被激活,在细胞膜小窝中发现了一个信号转导途径的几个元件,包括血管紧张素II 1型受体、NADPH氧化酶亚型1(Nox 1)的催化单位、G蛋白和表皮生长因子受体。我们将采用分子生物学、细胞生物学和生物化学方法相结合的方法,在子宫平滑肌细胞系中研究以下特定目标:1)血管紧张素II在子宫平滑肌细胞中NADPH氧化酶表达和激活的调节作用; 2)NADPH氧化酶在血管紧张素II受体介导的子宫平滑肌生长(肥大)和信号传导中的作用。目前,活性氧在产科病理学中的作用引起了人们极大的兴趣。众所周知,许多早产病例与感染有关,其中细胞因子诱导活性氧产生。活性氧簇的过度产生导致收缩失败、僵硬和钙超载。因此,我们预测血管紧张素Ⅱ-NADPH氧化酶-活性氧途径在分娩过程中也发挥作用。
项目成果
期刊论文数量(1)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
XIAOLAN CUI其他文献
XIAOLAN CUI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('XIAOLAN CUI', 18)}}的其他基金
NADPH Oxidase/Angiotensin II-Myometrial Hypertrophy
NADPH氧化酶/血管紧张素II-子宫肌层肥大
- 批准号:
7086012 - 财政年份:2006
- 资助金额:
$ 7.45万 - 项目类别:
相似海外基金
Early endothelial function activation by angiotensin II receptor blockers prevents vascular damage in a model of diabetes
血管紧张素 II 受体阻滞剂早期激活内皮功能可预防糖尿病模型中的血管损伤
- 批准号:
493141 - 财政年份:2023
- 资助金额:
$ 7.45万 - 项目类别:
Clinical benefits and mechanism of action of angiotensin-II receptor blocker on Cardiovascular remodeling in patients with repaired coarctation of aorta
血管紧张素II受体阻滞剂对主动脉缩窄修复患者心血管重塑的临床疗效及作用机制
- 批准号:
10734120 - 财政年份:2023
- 资助金额:
$ 7.45万 - 项目类别:
Targeting cancer-associated fibroblasts and tumour hypoxia with angiotensin II receptor blockers
使用血管紧张素 II 受体阻滞剂靶向癌症相关成纤维细胞和肿瘤缺氧
- 批准号:
445961 - 财政年份:2021
- 资助金额:
$ 7.45万 - 项目类别:
Operating Grants
Antitumor effect of HCC and exosome microRNA by angiotensin II receptor blockers and molecular target drugs
血管紧张素II受体阻滞剂和分子靶向药物对HCC和外泌体microRNA的抗肿瘤作用
- 批准号:
19K17401 - 财政年份:2019
- 资助金额:
$ 7.45万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Pleiotropic activation of endothelial function by angiotensin II receptor blockers is crucial to their protective anti-vascular remodeling effects
血管紧张素 II 受体阻滞剂对内皮功能的多效性激活对其保护性抗血管重塑作用至关重要
- 批准号:
411570 - 财政年份:2019
- 资助金额:
$ 7.45万 - 项目类别:
Heterogeneity of Angiotensin II Receptor Blockers in the inhibition of Marfan-associated Aortic Root Dilation Independent of Blood Pressure Effects
血管紧张素 II 受体阻滞剂抑制马凡相关主动脉根部扩张的异质性,与血压影响无关
- 批准号:
391615 - 财政年份:2018
- 资助金额:
$ 7.45万 - 项目类别:
Relationship between serum EETs concentrations and cardiovascular events in patients taking angiotensin II receptor blockers
服用血管紧张素II受体阻滞剂的患者血清EETs浓度与心血管事件的关系
- 批准号:
26460229 - 财政年份:2014
- 资助金额:
$ 7.45万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
The development of new angiotensin II receptor vaccine
新型血管紧张素II受体疫苗的研制
- 批准号:
25870715 - 财政年份:2013
- 资助金额:
$ 7.45万 - 项目类别:
Grant-in-Aid for Young Scientists (B)
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8531707 - 财政年份:2012
- 资助金额:
$ 7.45万 - 项目类别:
Central GRK5 modulation of Angiotensin II receptor expression in heart failure
GRK5 对心力衰竭中血管紧张素 II 受体表达的中枢调节
- 批准号:
8397394 - 财政年份:2012
- 资助金额:
$ 7.45万 - 项目类别: